ANI Pharmaceuticals Inc (ANIP)

Quick ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Cash	US$ in thousands	221,121	193,078	161,707	67,757	48,228	56,281	63,385	76,911	100,300	15,254	24,261	25,073	7,864	17,900	27,702	20,414	62,332	59,673	40,589	38,233
Short-term investments	US$ in thousands	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—	—
Receivables	US$ in thousands	162,079	178,842	172,925	174,713	165,438	140,433	150,410	131,625	128,526	106,714	92,648	91,876	95,793	83,745	73,162	82,379	72,129	70,700	76,274	67,410
Total current liabilities	US$ in thousands	145,477	134,352	122,865	125,825	99,439	81,627	96,312	79,532	87,537	84,872	89,454	82,768	78,565	75,900	79,088	79,356	61,676	170,707	166,794	165,068
Quick ratio		2.63	2.77	2.72	1.93	2.15	2.41	2.22	2.62	2.61	1.44	1.31	1.41	1.32	1.34	1.28	1.30	2.18	0.76	0.70	0.64

December 31, 2023 calculation

Quick ratio = (Cash + Short-term investments + Receivables) ÷ Total current liabilities
= ($221,121K + $—K + $162,079K) ÷ $145,477K
= 2.63

The quick ratio of ANI Pharmaceuticals Inc has shown fluctuations over the past eight quarters, ranging from a low of 2.01 in Q1 2023 to a high of 2.85 in Q3 2023. Overall, the trend indicates a relatively healthy liquidity position, with the company consistently maintaining a quick ratio above 2. This suggests that ANI Pharmaceuticals has an adequate level of liquid assets to cover its short-term liabilities, providing a measure of financial stability. The peak quick ratio of 2.85 in Q3 2023 indicates a particularly strong ability to meet short-term obligations without relying on inventory, which can be a positive sign for investors and creditors. However, the dip to 2.01 in Q1 2023 may raise some concerns about liquidity management during that period. Further analysis and monitoring of the trend in the quick ratio can help in assessing the company's short-term financial health and management efficiency.